Market Cap 882.87M
Revenue (ttm) 0.00
Net Income (ttm) -244.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,609,700
Avg Vol 3,111,322
Day's Range N/A - N/A
Shares Out 269.99M
Stochastic %K 25%
Beta 2.18
Analysts Strong Sell
Price Target $8.57

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modifi...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 701 7914
Address:
188 East Blaine Street, Suite 400, Seattle, United States
Salehoz
Salehoz May. 4 at 2:46 PM
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 4 at 1:40 PM
$SMMT Good Morning ☕️ Hope everyone added on Friday. I did, doubled my position. Future Lung Cancer therapy. This will be $100 plus in a yrs time$AMLX to $40, $SANA & $RXRX $10 plus. Have a great week!
0 · Reply
cta7978
cta7978 May. 4 at 2:20 AM
$FATE FATE trades at a depressed 0.86 P/B with BVPS ~$1.80 and stock ~$1.53. Peers $IPSC (2.5x P/B) and $SANA (~5.5x P/B) suggest a rerate to $4.50–$9.90/share (or higher) at similar multiples. FATE is further ahead clinically with Phase 1 FT819 CAR-T data in autoimmune (SLE etc.) showing meaningful responses, while IPSC and SANA remain mostly pre-IND or earlier in comparable programs. Strong data could easily justify a 4–7x+ P/B premium given the iPSC leadership and de-risking. High risk/high reward—watch the next readouts. DYOR.
1 · Reply
SKIJK
SKIJK May. 3 at 2:24 PM
$SANA Insider Monkey Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
0 · Reply
SKIJK
SKIJK May. 3 at 2:22 PM
$SANA As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating potentially curative therapies that can be standardized and scaled for global use. The collaboration focuses on using Mayo Clinic’s multidisciplinary expertise to refine the clinical and operational protocols necessary for delivering SC451. Efforts will include optimizing product handling, refining surgical procedural techniques, and improving post-treatment care to ensure the therapy can be adopted across various clinical environments.
0 · Reply
BriOnH
BriOnH May. 1 at 5:41 PM
$SANA Still at the very tip of the iceberg of what the potential success of sc451 means for humanity. https://longevity.technology/news/a-one-shot-cure-for-diabetes-sana-biotechnology-makes-its-move/
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 1 at 1:27 PM
$AMLX Good Morning ☕️ Bio 💎s $SMMT $RXRX $SANA $DTIL
0 · Reply
SKIJK
SKIJK May. 1 at 1:19 PM
$SANA Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that can survive and function without the need for traditional immunosuppression or daily insulin injections.
0 · Reply
Kennyboy1234
Kennyboy1234 May. 1 at 12:30 PM
1 · Reply
GLPHOTOX
GLPHOTOX Apr. 30 at 5:41 PM
$SANA The train has left the station, next stop is $6
1 · Reply
Latest News on SANA
Sana Biotechnology to Present at March 2026 Investor Conferences

Feb 23, 2026, 4:05 PM EST - 2 months ago

Sana Biotechnology to Present at March 2026 Investor Conferences


Sana Biotech Stock — The Next '100-Bagger'?

Oct 15, 2025, 12:15 PM EDT - 7 months ago

Sana Biotech Stock — The Next '100-Bagger'?


Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 11:24 PM EDT - 9 months ago

Sana Biotechnology Announces Pricing of Public Offering


Two Biotech Stocks Poised For Big Moves On Monday

Jun 23, 2025, 7:39 AM EDT - 11 months ago

Two Biotech Stocks Poised For Big Moves On Monday

LCTX


This Biotech Stock Just Soared 240%. Why It Can Go Higher.

Jan 8, 2025, 7:25 AM EST - 1 year ago

This Biotech Stock Just Soared 240%. Why It Can Go Higher.


Salehoz
Salehoz May. 4 at 2:46 PM
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 4 at 1:40 PM
$SMMT Good Morning ☕️ Hope everyone added on Friday. I did, doubled my position. Future Lung Cancer therapy. This will be $100 plus in a yrs time$AMLX to $40, $SANA & $RXRX $10 plus. Have a great week!
0 · Reply
cta7978
cta7978 May. 4 at 2:20 AM
$FATE FATE trades at a depressed 0.86 P/B with BVPS ~$1.80 and stock ~$1.53. Peers $IPSC (2.5x P/B) and $SANA (~5.5x P/B) suggest a rerate to $4.50–$9.90/share (or higher) at similar multiples. FATE is further ahead clinically with Phase 1 FT819 CAR-T data in autoimmune (SLE etc.) showing meaningful responses, while IPSC and SANA remain mostly pre-IND or earlier in comparable programs. Strong data could easily justify a 4–7x+ P/B premium given the iPSC leadership and de-risking. High risk/high reward—watch the next readouts. DYOR.
1 · Reply
SKIJK
SKIJK May. 3 at 2:24 PM
$SANA Insider Monkey Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
0 · Reply
SKIJK
SKIJK May. 3 at 2:22 PM
$SANA As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating potentially curative therapies that can be standardized and scaled for global use. The collaboration focuses on using Mayo Clinic’s multidisciplinary expertise to refine the clinical and operational protocols necessary for delivering SC451. Efforts will include optimizing product handling, refining surgical procedural techniques, and improving post-treatment care to ensure the therapy can be adopted across various clinical environments.
0 · Reply
BriOnH
BriOnH May. 1 at 5:41 PM
$SANA Still at the very tip of the iceberg of what the potential success of sc451 means for humanity. https://longevity.technology/news/a-one-shot-cure-for-diabetes-sana-biotechnology-makes-its-move/
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 1 at 1:27 PM
$AMLX Good Morning ☕️ Bio 💎s $SMMT $RXRX $SANA $DTIL
0 · Reply
SKIJK
SKIJK May. 1 at 1:19 PM
$SANA Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that can survive and function without the need for traditional immunosuppression or daily insulin injections.
0 · Reply
Kennyboy1234
Kennyboy1234 May. 1 at 12:30 PM
1 · Reply
GLPHOTOX
GLPHOTOX Apr. 30 at 5:41 PM
$SANA The train has left the station, next stop is $6
1 · Reply
Hashstockw
Hashstockw Apr. 30 at 3:25 PM
$SANA it is rising. Just broke a resistance
0 · Reply
SKIJK
SKIJK Apr. 30 at 4:39 AM
$SANA HEY, We will take $6
0 · Reply
GLPHOTOX
GLPHOTOX Apr. 30 at 12:03 AM
$SANA Good entry point here for the move back to $6;
1 · Reply
GLPHOTOX
GLPHOTOX Apr. 29 at 5:43 PM
$SANA good lord, where is the bottom on this ?
1 · Reply
BBraggHillBoys
BBraggHillBoys Apr. 28 at 10:59 AM
$SANA China's diabetes cell therapy is both proof of concept and competition for SANA.
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 28 at 12:52 AM
$SANA your 3.19 is a big deal longs i made a change to it today * mark it down on all your charts * for now moving forward * she has a large update which the dates have now been changed *
1 · Reply
JerryMalone32
JerryMalone32 Apr. 27 at 8:36 PM
$SANA news out. Preclinical data for fusogen will be presented in two weeks
1 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 27 at 1:48 PM
$RXRX Good Morning ☕️ My gem💎s. $AMLX $SMMT $SANA $DTIL
0 · Reply
mastergambler
mastergambler Apr. 26 at 6:46 PM
$SANA talk to the hand https://finance.yahoo.com/sectors/energy/articles/honda-ceo-says-no-chance-020000235.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAF1ciheoLDy6UPKql6Z0kYGoC1nJnve4357puH0QXPrMdP47kdTmW0_Lu3-wE9caqHTkUGA4KUDml3prZyUzYXgju-ua77JejfbLbQ9miMQdaLmgOtFwEFvN5f39_Wu1u2GGCLg85rQmYhDmQhkx4Uv793zzLiBs37UmRzg-okN5
0 · Reply
SKIJK
SKIJK Apr. 26 at 3:24 PM
$SANA Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
0 · Reply
SKIJK
SKIJK Apr. 26 at 3:23 PM
$SANA Analyst consensus: Eight analysts give Sana a consensus rating of "Moderate Buy" (six buys, one hold, one sell) with an average 1‑year target price of $8.20. Current valuation and trading: Shares recently opened around $3.52 with a market cap near $939M, a negative PE of -3.63, a 52‑week range of $1.59–$6.55, and 50/200‑day moving averages of $3.47 and $4.12 respectively. Fundamentals and ownership: Sana missed quarterly EPS (‑$0.16 vs. ‑$0.13 expected) and analysts forecast about ‑$1.16 for the year, while institutional and hedge fund ownership is high at roughly 88.23% with notable stake increases by firms like JPMorgan and Baillie Gifford.
0 · Reply
SKIJK
SKIJK Apr. 26 at 3:21 PM
$SANA BECAUSE the Chinese are honest,truth, and never exagerate, we all know this
0 · Reply